The IVD market in BRIC countries is highly competitive and fragmented in nature. Prominent players in the IVD market are Roche Diagnostics (Switzerland), Abbott Laboratories Inc. (U.S.), Siemens Healthineers (Germany), Danaher Corporation (U.S.), and Thermo Fisher Scientific Inc. (U.S.). These players accounted for the largest market share in 2016. Other players in this market include Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux (France), Becton, Dickinson and Company (U.S.), Johnson & Johnson (U.S.), Diasorin S.P.A. (Italy), Ortho-Clinical Diagnostics, Inc. (U.S.), and QIAGEN N.V. (Germany). A majority of the leading players in this market are present in BRIC countries as well.
Roche Diagnostics held the leading position in the IVD market in BRIC countries in 2016. Its prominence in this market can be attributed to its diversified product portfolio that includes a wide range of products for in vitro diagnosis. The company strongly invests in R&D activities to improve its existing product portfolio, as it has a strong pipeline of products for the growing market. The company has a wide geographic presence across North America, Europe, the Middle East & Africa, and Asia. The company has also focused on a variety of strategies, such as agreement, product launch, and expansion, to increase its share in the IVD market. For instance, in January 2017, Roche launched the cobas m 511, an integrated hematology analyzer.
Abbott Laboratories Inc. is another leading company in the IVD market in BRIC countries. The company has maintained its position through its strong presence across the globe, covering major markets such as North America, Europe, and Asia-Pacific. The company has a strong product portfolio, and its FDA and CE Mark-approved products have helped it to further enhance its presence in the market. The company mainly focused on product approvals and product launches, followed by agreements and collaborations, to maintain its leading position and increase its market share. For instance, in January 2017, Abbott obtained the CE mark approval for the Alinitys System used for blood and plasma screening.
In the past three years, a majority of the top players have adopted product launches; acquisitions, agreements, collaborations, and partnerships; and geographic expansions as their key growth strategies. Product launch was the preferred strategy adopted by key players in the IVD market in BRIC countries.
IVD Market in BRIC by Product & Service (Instruments, Reagents, Software), Technology (Immunoassay, Hematology, Microbiology), Application (Diabetes, Cardiology, Infectious Diseases), Country (Brazil, Russia, India, China) - Forecast to 2022
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE